ID
13439
Descrição
Antibiotic-associated diarrhoea (AAD) is a frequent condition in hospitalised patients receiving antibiotic treatment. The same is true for Clostridium difficile-associated diarrhoea (CDAD) with even more grave consequences of increased morbidity and mortality. The development and evaluation of preventive strategies is one key public health challenge. In the absence of clinically evaluated alternatives, probiotics have been suggested to be beneficial for the prevention of AAD and CDAD. However, data have so far been inconclusive and recently published meta-analyses strongly recommended large state-of-the-art clinical trials on probiotic substances for the prevention of AAD and CDAD. Since the efficacy, side-effects and modes of action of different probiotic bacteria and yeast are strain specific, benefits and risks cannot be generalised. The non-pathogenic yeast Saccharomyces cerevisiae var. boulardii (Sac. boulardii) is considered the most promising probiotic substance for the prevention of AAD and CDAD. We carry out a randomised, placebo controlled, double blind multicentre clinical trial to evaluate Sac. boulardii for the indication of prevention of AAD and CDAD in 1520 adult, hospitalised patients.
Palavras-chave
Versões (3)
- 10/02/2016 10/02/2016 -
- 10/02/2016 10/02/2016 - Julian Varghese
- 11/02/2016 11/02/2016 -
Transferido a
11 de fevereiro de 2016
DOI
Para um pedido faça login.
Licença
Creative Commons BY-NC 3.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
SacBo PZ: Case Report Form AE Termination Signature Early Study Termination DRKS00000084 NCT01143272
SacBo PZ: Case Report Form AE Termination Signature Early Study Termination NCT01143272
Similar models
SacBo PZ: Case Report Form AE Termination Signature Early Study Termination NCT01143272
C0011008 (UMLS CUI [1,2])
C0009566 (UMLS CUI [2])